Walking Assist Devices Market by Product Type (Cane, Crutch, Exoskeleton), Technology (Active, Passive), End User, Distribution Channel - Global Forecast 2025-2032
Description
The Walking Assist Devices Market was valued at USD 3.65 billion in 2024 and is projected to grow to USD 3.91 billion in 2025, with a CAGR of 7.38%, reaching USD 6.46 billion by 2032.
A clear framing of the walking assist device landscape that links product diversity, user needs, and commercial dynamics to strategic priorities
Walking assist devices are at a pivotal intersection of clinical need, demographic change, and technological innovation. Advances in materials science, sensors, and actuation have brought a wider array of usable options to clinicians, caregivers, and independent users. At the same time, ageing populations and longer survival with chronic conditions are increasing daily demand for products that restore mobility while minimising caregiver burden and downstream complications. This introduction frames the executive summary by clarifying the device landscape, the user contexts that shape choice, and the broader forces reshaping procurement and product development.
The product set spans simple mechanical aids through sophisticated powered systems, and each category delivers distinctive clinical outcomes, training needs, and reimbursement implications. End-user environments range from in-home supports to acute hospital settings and specialised rehabilitation facilities, and distribution channels reflect both traditional clinical procurement routes and emergent e-commerce pathways. Against this backdrop, this summary synthesises technical trends, policy shifts, and commercial dynamics to support strategic decisions that link product design, supply chain resilience, and go-to-market execution in an increasingly complex ecosystem.
How converging technologies, shifting reimbursement expectations, and new commercial entrants are redefining clinical pathways and distribution for mobility aids
The device landscape is undergoing transformative shifts driven by converging technological, clinical, and commercial forces. Sensor miniaturisation and low-cost electronics have enabled smarter passive braces and walkers to provide real-time feedback and telemetry, while modular battery and actuator improvements are expanding the applicability of powered exoskeletons beyond specialised centres. These advances are reshaping clinical pathways and creating new value propositions around remote monitoring, adherence, and functional outcomes, which in turn alter the expectations of payers and procurement teams.
Parallel to technological progress, regulatory frameworks and reimbursement paradigms are adapting to evidence generation that emphasises functional gains and long-term cost offsets. Non-traditional entrants and partnerships across orthopaedic device firms, robotics start-ups, and digital health vendors are accelerating cross-disciplinary product development and bringing efficiency pressures into traditional supply chains. Moreover, distribution is fragmenting: hospital clinics remain critical for acute and post-operative care, but online pharmacies and retail pharmacy channels are expanding access for chronic and consumer-grade solutions. Consequently, successful strategies are those that respond to integrated clinical workflows, prioritise human-centred design for diverse end users, and align commercial models with evolving payment and procurement mechanisms.
The cumulative effects of tariff adjustments in 2025 have reshaped supply chain choices, cost structures, and regional sourcing strategies across device categories
The introduction of higher tariff measures originating from policy shifts in 2025 has imposed upward pressure on many components and finished goods used in walking assist devices, with a pronounced effect on products whose supply chains depend on cross-border manufacturing of mechanical subsystems and electronic modules. Tariffs have exposed vulnerabilities in previously lean global production networks, accelerating conversations around supplier diversification, regional sourcing, and nearshoring of critical subassemblies to preserve margins and delivery reliability. Organizations are reassessing long-term procurement contracts and renegotiating terms with suppliers to incorporate tariff contingencies and increased logistics costs.
Beyond cost impacts, tariffs have altered competitive dynamics by changing relative cost structures across product categories. Manufacturers of lower-tech devices such as canes and standard walkers have found more immediate levers to mitigate tariffs through localised manufacturing and simplified designs, while producers of powered exoskeletons and motorised aids face more complex challenges due to dependence on specialised electronic components and actuator imports. In response, firms are pursuing modular architectures that allow substitution of regionally sourced parts, intensifying efforts to obtain more favourable tariff classifications through compliance and customs consultancy, and accelerating investments in manufacturing footprints closer to end markets. These adaptations are already shaping procurement timelines, warranty frameworks, and capital allocation decisions across the industry.
Detailed segmentation insights reveal where product design, end-user needs, distribution choices, and technology modalities converge to create strategic priorities
Insightful segmentation is essential to understanding where innovation and commercial opportunity are concentrated within the walking assist device area. When viewed through the lens of product type, the landscape includes canes, crutches, exoskeletons, orthoses, and walkers; within canes, quad and single‑point variants address different stability and user-mobility profiles, while crutches subdivide into axillary and forearm formats that reflect patient endurance and upper-limb support needs. Exoskeleton classes range from full-body systems that assist complex gait patterns to lower-limb devices targeted at ambulation support, and orthoses span ankle, hip, and knee braces each designed for joint-specific biomechanical intervention. Walkers present clear distinctions between rollator and standard designs that influence maneuverability, user independence, and fall-prevention outcomes.
End user contexts create distinct product performance and support requirements, with home care settings prioritising ease of use, portability, and discreet aesthetics; hospitals emphasising sterilisation, durability, and integration into care pathways; and rehabilitation centres demanding devices that enable progressive loading, clinician-adjustable parameters, and performance tracking. Distribution routes also shape how products are packaged, priced, and supported: hospital clinics function within procurement cycles and clinical procurement teams, online pharmacies offer convenience and broader reach for consumer-focused devices, and retail pharmacies provide immediate availability and localised advice. Finally, technology classifications between active and passive systems carry implications for regulatory pathways, service requirements, and lifecycle costs: active devices include motorised and pneumatic actuation options requiring power management and maintenance protocols, while passive solutions employ hydraulic or spring-based mechanisms that prioritise mechanical reliability and low maintenance. Taken together, these segmentation dimensions create a matrix of clinical needs, operational constraints, and commercial channels that should guide prioritisation of R&D investments, distribution strategies, and support services.
Regional differences in reimbursement frameworks, manufacturing incentives, and care delivery models are shaping device adoption and commercial strategy
Regional dynamics influence product design, regulatory approaches, and distribution strategies in meaningful ways. In the Americas, demand patterns favour solutions that balance clinical efficacy with home-use convenience, and the region’s reimbursement environment and institutional procurement channels shape the adoption curve for higher-cost active systems. Manufacturers face expectations for robust clinical evidence and strong post-market surveillance, but also benefit from advanced reimbursement frameworks in parts of the region that can support novel device introductions.
Europe, Middle East & Africa presents a heterogeneous landscape in which regulatory harmonisation efforts coexist with widely varying purchasing power and healthcare delivery models. This region often prioritises devices that demonstrate cost-effectiveness across diverse health systems, and there is growing interest in devices that reduce caregiver burden in ageing populations. In Asia-Pacific, rapid urbanisation, expanding private healthcare provision, and rising investment in local manufacturing are accelerating uptake, while governments in several countries are incentivising domestic production and technology transfer. Across all regions, supply chain resilience, compliance with local standards, and culturally informed design are key determinants of commercial success, and regional strategies must account for differences in clinician training, patient expectations, and distribution infrastructure.
Competitive dynamics and supplier ecosystems are converging around clinical evidence, modular component partnerships, and scalable service models
Competitive dynamics are being reshaped by a mix of established medical-device firms, robotics and mechatronics specialists, component suppliers, and agile start-ups focused on user experience and digital integration. Mature manufacturers continue to leverage scale, clinical relationships, and regulatory expertise to commercialise institutional-grade walkers, braces, and rehabilitation products. In parallel, technology-oriented entrants are introducing sensor-enabled passive devices and modular exoskeleton components that prioritise interoperability with digital therapy platforms and remote monitoring solutions.
Supplier ecosystems are evolving: tier‑one component suppliers are increasingly partnering with device assemblers to co-develop motor, actuator, and battery subassemblies that meet tariff and performance constraints, while distributors and pharmacy chains are expanding their clinical advisory capabilities to support product adoption outside hospital settings. Service models are also differentiating; some firms offer bundled installation, training, and maintenance contracts for powered systems, while others emphasise low-touch designs that lower the burden on clinical staff and caregivers. For buyers and strategic partners, the most important competitive attribute is the ability to marry clinical evidence with operational scalability and a predictable total cost of ownership across the device lifecycle.
Practical strategic moves for decision-makers to build resilient supply chains, strengthen clinical adoption, and expand commercial reach across channels
Industry leaders should adopt a multi-dimensional strategy that aligns product development, supply chain resilience, and commercial execution. Prioritise modular architectures that decouple electronic and mechanical subassemblies, enabling selective localisation of components and accelerated substitution if tariff regimes or logistics constraints change. Invest in usability testing across end-user contexts-home care, hospital, and rehabilitation settings-to ensure product interfaces and training materials reduce adoption friction and minimise the need for costly clinician time.
On the commercial side, diversify distribution by strengthening relationships with hospital clinics while expanding presence through online and retail pharmacies for consumer-oriented lines. Build evidence-generation plans that demonstrate functional outcomes and caregiver impact, not only device metrics, to resonate with payers and procurement teams. Finally, enhance after-sales service capabilities for active devices through remote diagnostics and predictive maintenance, and explore partnerships with component suppliers to secure long-term pricing and supply commitments. These actions will protect margins, accelerate adoption, and position organisations to capitalise on the evolving demand for mobility-support solutions.
A mixed-methods research approach that integrates primary stakeholder interviews, observational testing, and rigorous secondary verification to ensure actionable findings
The research underpinning this executive summary relied on a structured, mixed-methods approach that combined primary stakeholder engagement with rigorous secondary synthesis and data triangulation. Primary inputs included in-depth interviews with clinicians, procurement specialists, product engineers, and distribution partners, supplemented by device-level usability testing observations in clinical and home environments to capture real-world interaction patterns and failure modes. Secondary research synthesised regulatory documents, standards guidance, patent filings, and public company disclosures to contextualise technology trajectories and compliance expectations.
Findings were validated through cross-checks among independent data sources and iterative discussions with technical advisors and clinical experts to ensure practical relevance. Where possible, technological claims were corroborated by peer-reviewed literature and product technical specifications. The methodology acknowledges limitations in rapidly evolving tariff and policy environments, and the conclusions emphasise directional insights and strategic options rather than precise financial estimates. This approach supports decision-making by combining qualitative depth with disciplined verification of key technical and commercial assumptions.
A concise synthesis highlighting how design, supply-chain agility, and evidence-driven commercial strategies determine long-term success in mobility solutions
In conclusion, walking assist devices represent a dynamic sector where technology advances, demographic pressures, and policy changes intersect to create both risk and opportunity. Success requires a pragmatic combination of human-centred product design, resilient and flexible manufacturing strategies, and evidence-driven commercial engagement with clinicians, payers, and distribution partners. The 2025 tariff environment has heightened the need for supply-chain agility and localisation strategies, while expanding digital capabilities and modular product architectures are opening new routes to clinical and consumer adoption.
Decision-makers who prioritise interoperability, ease of use, and demonstrable functional outcomes will be best positioned to navigate the evolving regulatory and procurement landscape. Inevitable shifts in competitive structure favour organisations that can partner effectively across the component ecosystem, scale service offerings for active devices, and tailor distribution strategies to regional realities. The synthesis presented here is intended to inform strategic prioritisation and to accelerate decisions about product roadmaps, sourcing, and commercial investments that support long-term growth and improved mobility outcomes for diverse patient populations.
Note: PDF & Excel + Online Access - 1 Year
A clear framing of the walking assist device landscape that links product diversity, user needs, and commercial dynamics to strategic priorities
Walking assist devices are at a pivotal intersection of clinical need, demographic change, and technological innovation. Advances in materials science, sensors, and actuation have brought a wider array of usable options to clinicians, caregivers, and independent users. At the same time, ageing populations and longer survival with chronic conditions are increasing daily demand for products that restore mobility while minimising caregiver burden and downstream complications. This introduction frames the executive summary by clarifying the device landscape, the user contexts that shape choice, and the broader forces reshaping procurement and product development.
The product set spans simple mechanical aids through sophisticated powered systems, and each category delivers distinctive clinical outcomes, training needs, and reimbursement implications. End-user environments range from in-home supports to acute hospital settings and specialised rehabilitation facilities, and distribution channels reflect both traditional clinical procurement routes and emergent e-commerce pathways. Against this backdrop, this summary synthesises technical trends, policy shifts, and commercial dynamics to support strategic decisions that link product design, supply chain resilience, and go-to-market execution in an increasingly complex ecosystem.
How converging technologies, shifting reimbursement expectations, and new commercial entrants are redefining clinical pathways and distribution for mobility aids
The device landscape is undergoing transformative shifts driven by converging technological, clinical, and commercial forces. Sensor miniaturisation and low-cost electronics have enabled smarter passive braces and walkers to provide real-time feedback and telemetry, while modular battery and actuator improvements are expanding the applicability of powered exoskeletons beyond specialised centres. These advances are reshaping clinical pathways and creating new value propositions around remote monitoring, adherence, and functional outcomes, which in turn alter the expectations of payers and procurement teams.
Parallel to technological progress, regulatory frameworks and reimbursement paradigms are adapting to evidence generation that emphasises functional gains and long-term cost offsets. Non-traditional entrants and partnerships across orthopaedic device firms, robotics start-ups, and digital health vendors are accelerating cross-disciplinary product development and bringing efficiency pressures into traditional supply chains. Moreover, distribution is fragmenting: hospital clinics remain critical for acute and post-operative care, but online pharmacies and retail pharmacy channels are expanding access for chronic and consumer-grade solutions. Consequently, successful strategies are those that respond to integrated clinical workflows, prioritise human-centred design for diverse end users, and align commercial models with evolving payment and procurement mechanisms.
The cumulative effects of tariff adjustments in 2025 have reshaped supply chain choices, cost structures, and regional sourcing strategies across device categories
The introduction of higher tariff measures originating from policy shifts in 2025 has imposed upward pressure on many components and finished goods used in walking assist devices, with a pronounced effect on products whose supply chains depend on cross-border manufacturing of mechanical subsystems and electronic modules. Tariffs have exposed vulnerabilities in previously lean global production networks, accelerating conversations around supplier diversification, regional sourcing, and nearshoring of critical subassemblies to preserve margins and delivery reliability. Organizations are reassessing long-term procurement contracts and renegotiating terms with suppliers to incorporate tariff contingencies and increased logistics costs.
Beyond cost impacts, tariffs have altered competitive dynamics by changing relative cost structures across product categories. Manufacturers of lower-tech devices such as canes and standard walkers have found more immediate levers to mitigate tariffs through localised manufacturing and simplified designs, while producers of powered exoskeletons and motorised aids face more complex challenges due to dependence on specialised electronic components and actuator imports. In response, firms are pursuing modular architectures that allow substitution of regionally sourced parts, intensifying efforts to obtain more favourable tariff classifications through compliance and customs consultancy, and accelerating investments in manufacturing footprints closer to end markets. These adaptations are already shaping procurement timelines, warranty frameworks, and capital allocation decisions across the industry.
Detailed segmentation insights reveal where product design, end-user needs, distribution choices, and technology modalities converge to create strategic priorities
Insightful segmentation is essential to understanding where innovation and commercial opportunity are concentrated within the walking assist device area. When viewed through the lens of product type, the landscape includes canes, crutches, exoskeletons, orthoses, and walkers; within canes, quad and single‑point variants address different stability and user-mobility profiles, while crutches subdivide into axillary and forearm formats that reflect patient endurance and upper-limb support needs. Exoskeleton classes range from full-body systems that assist complex gait patterns to lower-limb devices targeted at ambulation support, and orthoses span ankle, hip, and knee braces each designed for joint-specific biomechanical intervention. Walkers present clear distinctions between rollator and standard designs that influence maneuverability, user independence, and fall-prevention outcomes.
End user contexts create distinct product performance and support requirements, with home care settings prioritising ease of use, portability, and discreet aesthetics; hospitals emphasising sterilisation, durability, and integration into care pathways; and rehabilitation centres demanding devices that enable progressive loading, clinician-adjustable parameters, and performance tracking. Distribution routes also shape how products are packaged, priced, and supported: hospital clinics function within procurement cycles and clinical procurement teams, online pharmacies offer convenience and broader reach for consumer-focused devices, and retail pharmacies provide immediate availability and localised advice. Finally, technology classifications between active and passive systems carry implications for regulatory pathways, service requirements, and lifecycle costs: active devices include motorised and pneumatic actuation options requiring power management and maintenance protocols, while passive solutions employ hydraulic or spring-based mechanisms that prioritise mechanical reliability and low maintenance. Taken together, these segmentation dimensions create a matrix of clinical needs, operational constraints, and commercial channels that should guide prioritisation of R&D investments, distribution strategies, and support services.
Regional differences in reimbursement frameworks, manufacturing incentives, and care delivery models are shaping device adoption and commercial strategy
Regional dynamics influence product design, regulatory approaches, and distribution strategies in meaningful ways. In the Americas, demand patterns favour solutions that balance clinical efficacy with home-use convenience, and the region’s reimbursement environment and institutional procurement channels shape the adoption curve for higher-cost active systems. Manufacturers face expectations for robust clinical evidence and strong post-market surveillance, but also benefit from advanced reimbursement frameworks in parts of the region that can support novel device introductions.
Europe, Middle East & Africa presents a heterogeneous landscape in which regulatory harmonisation efforts coexist with widely varying purchasing power and healthcare delivery models. This region often prioritises devices that demonstrate cost-effectiveness across diverse health systems, and there is growing interest in devices that reduce caregiver burden in ageing populations. In Asia-Pacific, rapid urbanisation, expanding private healthcare provision, and rising investment in local manufacturing are accelerating uptake, while governments in several countries are incentivising domestic production and technology transfer. Across all regions, supply chain resilience, compliance with local standards, and culturally informed design are key determinants of commercial success, and regional strategies must account for differences in clinician training, patient expectations, and distribution infrastructure.
Competitive dynamics and supplier ecosystems are converging around clinical evidence, modular component partnerships, and scalable service models
Competitive dynamics are being reshaped by a mix of established medical-device firms, robotics and mechatronics specialists, component suppliers, and agile start-ups focused on user experience and digital integration. Mature manufacturers continue to leverage scale, clinical relationships, and regulatory expertise to commercialise institutional-grade walkers, braces, and rehabilitation products. In parallel, technology-oriented entrants are introducing sensor-enabled passive devices and modular exoskeleton components that prioritise interoperability with digital therapy platforms and remote monitoring solutions.
Supplier ecosystems are evolving: tier‑one component suppliers are increasingly partnering with device assemblers to co-develop motor, actuator, and battery subassemblies that meet tariff and performance constraints, while distributors and pharmacy chains are expanding their clinical advisory capabilities to support product adoption outside hospital settings. Service models are also differentiating; some firms offer bundled installation, training, and maintenance contracts for powered systems, while others emphasise low-touch designs that lower the burden on clinical staff and caregivers. For buyers and strategic partners, the most important competitive attribute is the ability to marry clinical evidence with operational scalability and a predictable total cost of ownership across the device lifecycle.
Practical strategic moves for decision-makers to build resilient supply chains, strengthen clinical adoption, and expand commercial reach across channels
Industry leaders should adopt a multi-dimensional strategy that aligns product development, supply chain resilience, and commercial execution. Prioritise modular architectures that decouple electronic and mechanical subassemblies, enabling selective localisation of components and accelerated substitution if tariff regimes or logistics constraints change. Invest in usability testing across end-user contexts-home care, hospital, and rehabilitation settings-to ensure product interfaces and training materials reduce adoption friction and minimise the need for costly clinician time.
On the commercial side, diversify distribution by strengthening relationships with hospital clinics while expanding presence through online and retail pharmacies for consumer-oriented lines. Build evidence-generation plans that demonstrate functional outcomes and caregiver impact, not only device metrics, to resonate with payers and procurement teams. Finally, enhance after-sales service capabilities for active devices through remote diagnostics and predictive maintenance, and explore partnerships with component suppliers to secure long-term pricing and supply commitments. These actions will protect margins, accelerate adoption, and position organisations to capitalise on the evolving demand for mobility-support solutions.
A mixed-methods research approach that integrates primary stakeholder interviews, observational testing, and rigorous secondary verification to ensure actionable findings
The research underpinning this executive summary relied on a structured, mixed-methods approach that combined primary stakeholder engagement with rigorous secondary synthesis and data triangulation. Primary inputs included in-depth interviews with clinicians, procurement specialists, product engineers, and distribution partners, supplemented by device-level usability testing observations in clinical and home environments to capture real-world interaction patterns and failure modes. Secondary research synthesised regulatory documents, standards guidance, patent filings, and public company disclosures to contextualise technology trajectories and compliance expectations.
Findings were validated through cross-checks among independent data sources and iterative discussions with technical advisors and clinical experts to ensure practical relevance. Where possible, technological claims were corroborated by peer-reviewed literature and product technical specifications. The methodology acknowledges limitations in rapidly evolving tariff and policy environments, and the conclusions emphasise directional insights and strategic options rather than precise financial estimates. This approach supports decision-making by combining qualitative depth with disciplined verification of key technical and commercial assumptions.
A concise synthesis highlighting how design, supply-chain agility, and evidence-driven commercial strategies determine long-term success in mobility solutions
In conclusion, walking assist devices represent a dynamic sector where technology advances, demographic pressures, and policy changes intersect to create both risk and opportunity. Success requires a pragmatic combination of human-centred product design, resilient and flexible manufacturing strategies, and evidence-driven commercial engagement with clinicians, payers, and distribution partners. The 2025 tariff environment has heightened the need for supply-chain agility and localisation strategies, while expanding digital capabilities and modular product architectures are opening new routes to clinical and consumer adoption.
Decision-makers who prioritise interoperability, ease of use, and demonstrable functional outcomes will be best positioned to navigate the evolving regulatory and procurement landscape. Inevitable shifts in competitive structure favour organisations that can partner effectively across the component ecosystem, scale service offerings for active devices, and tailor distribution strategies to regional realities. The synthesis presented here is intended to inform strategic prioritisation and to accelerate decisions about product roadmaps, sourcing, and commercial investments that support long-term growth and improved mobility outcomes for diverse patient populations.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
188 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of ai-powered gait analysis software for personalized walking support
- 5.2. Development of lightweight carbon fiber exoskeleton frames for enhanced mobility
- 5.3. Incorporation of iot connectivity for remote monitoring and real-time device adjustments
- 5.4. Advancements in rechargeable lithium polymer batteries for extended walking device use
- 5.5. Customizable orthotic interfaces designed using 3d scanning for patient specific fit improvement
- 5.6. Expansion of reimbursement policies to include robotic walking assist devices in elderly care settings
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Walking Assist Devices Market, by Product Type
- 8.1. Cane
- 8.1.1. Quad Cane
- 8.1.2. Single-Point Cane
- 8.2. Crutch
- 8.2.1. Axillary Crutch
- 8.2.2. Forearm Crutch
- 8.3. Exoskeleton
- 8.3.1. Full Body
- 8.3.2. Lower Limb
- 8.4. Orthosis
- 8.4.1. Ankle Brace
- 8.4.2. Hip Brace
- 8.4.3. Knee Brace
- 8.5. Walker
- 8.5.1. Rollator Walker
- 8.5.2. Standard Walker
- 9. Walking Assist Devices Market, by Technology
- 9.1. Active
- 9.1.1. Motorized
- 9.1.2. Pneumatic
- 9.2. Passive
- 9.2.1. Hydraulic
- 9.2.2. Spring Based
- 10. Walking Assist Devices Market, by End User
- 10.1. Home Care
- 10.2. Hospital
- 10.3. Rehabilitation Center
- 11. Walking Assist Devices Market, by Distribution Channel
- 11.1. Hospital Clinics
- 11.2. Online Pharmacy
- 11.3. Retail Pharmacy
- 12. Walking Assist Devices Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Walking Assist Devices Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Walking Assist Devices Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Bionik Labs Corp.
- 15.3.2. Cyberdyne Inc.
- 15.3.3. Ekso Bionics Holdings, Inc.
- 15.3.4. Hocoma AG
- 15.3.5. Myomo, Inc.
- 15.3.6. Ottobock SE & Co. KGaA
- 15.3.7. Parker-Hannifin Corporation
- 15.3.8. Permobil Inc
- 15.3.9. Pride Mobility Products Corporation
- 15.3.10. ReWalk Robotics Ltd.
- 15.3.11. RxFunction, Inc.
- 15.3.12. Shenzhen Zuowei Technology Co., Ltd.
- 15.3.13. Stryker Corporation
- 15.3.14. Sunrise Medical (US) LLC
- 15.3.15. Synetik ErgoCare
- 15.3.16. Wandercraft SAS
- 15.3.17. Yattil Industry Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
